Association Between Ambroxol at the Usual Dose and the Risk of Parkinson’s Disease in Chronic Lung Disease

참고문헌 (9)

1. Gegg ME, "Glucocerebrosidase-associated Parkinson disease : pathogenic mechanisms and potential drug treatments", Neurobiol Dis, 166, pp.105663~ (2022)
2. Mullin S, "Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations : a nonrandomized, noncontrolled trial", JAMA Neurol, 77, pp.427~434 (2020)
3. Jiang W, "Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease", J Hum Genet, 65, pp.345~349 (2020)
4. Kim YM, "Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy", J Med Genet, 57, pp.124~131 (2020)
5. Narita A, "Ambroxol chaperone therapy for neuronopathic Gaucher disease : a pilot study", Ann Clin Transl Neurol, 3, pp.200~215 (2016)
6. Park J, "The associations between changes in hepatic steatosis and heart failure and mortality : a nationwide cohort study", Cardiovasc Diabetol, 21, pp.287~ (2022)
7. Migdalska-Richards A, "Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate", Synapse, 71, pp.e21967~ (2017)
8. Migdalska-Richards A, "Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice", Ann Neurol, 80, pp.766~775 (2016)
9. Santiago JA, "Biological and clinical implications of comorbidities in Parkinson’s disease", Front Aging Neurosci, 9, pp.394~ (2017)

관련 논문AI추천